Dr. McDermott on Single-Agent Nivolumab in RCC
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses nivolumab (Opdivo) as a single-agent for the treatment of patients with renal cell carcinoma.
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses nivolumab (Opdivo) as a single agent for the treatment of patients with renal cell carcinoma (RCC).
Nivolumab is currently FDA approved for patients with RCC who have failed VEGF therapy in the second-line, but McDermott said that its therapeutic index and toxicity profile makes it a good candidate for first-line treatment.
In order to move this agent to the frontline, more work must be done to develop biomarkers to select patients who would benefit from single-agent nivolumab.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
